Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab-Reference-Cited by-同舟云学术

Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab

Published:2008-09 Issue:9 Volume:19 Page:1629-1633
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Bishton M.J.,Leahy M.F.,Hicks R.J.,Turner J.H.,McQuillan A.D.,Seymour J.F.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/19/9/1629/545509/mdn172.pdf

Reference20 articles.

1. Follicular lymphoma: prognostic factors for response and survival;Gallagher;J Clin Oncol,1986

2. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

3. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial;van Oers;Blood,2006

4. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)

5. The radioisotope contributes significantly to the activity of radioimmunotherapy;Davis;Clin Cancer Res,2004

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radioimmunotherapy as the first line of treatment in non-Hodgkin lymphoma;Immunotherapy;2018-06

2. Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma;Future Oncology;2015-05

3. Phase II study of first-line131I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic18F-fluorodeoxyglucose positron emission tomography;Leukemia & Lymphoma;2014-08-19

4. Personalized Dosimetry of 131I-Rituximab Radioimmunotherapy of Non-Hodgkin Lymphoma Defined by Pharmacokinetics in Bone Marrow and Blood;Cancer Biotherapy and Radiopharmaceuticals;2014-02

5. Treatment With Thyroid Hormone;Endocrine Reviews;2014-01-16